Synonyms: BMY-28142 | BMY28142 | CFPM | Maxipime® | Renapime®
cefepime is an approved drug (FDA (1996), UK (2017))
Compound class:
Synthetic organic
Comment: Cefepime is a semisynthetic, broad-spectrum, fourth-generation cephalosporin antibacterial [1-2]. It was removed from the World Health Organization's List of Essential Medicines in 2019.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03840148 | Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections | Phase 3 Interventional | VenatoRx Pharmaceuticals, Inc. | A study examining the combination of the 4th gen cephalosporin cefepime and the broad-spectrum β-lactamse inhibitor taniborbactam. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com |